Amibegron

Amibegron
	240px
Systematic (IUPAC) name
	Ethyl ([(7S)-7-([(2R)-2-(3-chlorophenyl)-2-hydroxyethyl]amino)-5,6,7,8-tetrahydronaphthalen-2-yl]oxy)acetate
Identifiers
CAS Number	121524-09-2
ATC code	none
PubChem	CID 3035442
IUPHAR/BPS	568
Chemical data
Formula	C22H26ClNO4
Molar mass	403.898 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Amibegron (SR-58,611A) is a drug developed by Sanofi-Aventis which acts as a selective agonist for the β3 adrenergic receptor. It is the first orally active β3 agonist developed that is capable of entering the Central Nervous System, and has antidepressant and anxiolytic effects.^[1]^[2]

On July 31, 2008, Sanofi-Aventis announced that it has decided to discontinue development of amibegron.^[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

35px	This drug article relating to the nervous system is a stub. You can help ssf by expanding it. v d e

↑ Stemmelin J, Cohen C, Terranova JP, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, Alonso R, Stahl SM, Keane P, Avenet P, Scatton B, le Fur G, Griebel G. Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology. 2008 Feb;33(3):574-87. PMID 17460614
↑ Overstreet DH, Stemmelin J, Griebel G. Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. Pharmacology, Biochemistry and Behaviour. 2008 Jun;89(4):623-6. PMID 18358519
↑ Second quarter 2008 results. July 31, 2008, retrieved March 9, 2009.